After nearly four years of technical research and clinical experiments, the KC-3000 biofeedback gastrointestinal motility instrument, a new product independently developed and designed by Kuancheng Science and Technology, has successfully obtained the Registration Certificate of Medical Devices of the People's Republic of China issued by Jiangsu Food and Drug Administration, and has obtained the qualification for marketing. The registration certificate number is SAXS 2018226072.

　　In recent years, with the change of life style and the acceleration of life rhythm, functional gastrointestinal diseases have become increasingly common. Clinically, this disease is mainly characterized by functional heartburn, globus hysteria, functional dyspepsia, irritable bowel syndrome, and its main symptoms include poststernal burning discomfort or pain, foreign body sensation in the throat, fullness after meals, early satiety, abdominal pain, belching, anorexia, diarrhea, constipation, and unclean defecation. Many patients are accompanied by insomnia, anxiety, depression, headache, and other symptoms, and the course of the disease is often more than 6 months. The symptoms of the disease are complex, difficult to diagnose, easy to recur, and seriously endanger the physical and mental health and quality of life of patients. At present, clinical treatment mainly relies on gastrointestinal motility drugs, but long-term medication is prone to side effects and drug resistance, and many patients are difficult to achieve satisfactory results.

　　In recent years, with the change of life style and the acceleration of life rhythm, functional gastrointestinal diseases have become increasingly common. Clinically, this disease is mainly characterized by functional heartburn, globus hysteria, functional dyspepsia, irritable bowel syndrome, and its main symptoms include poststernal burning discomfort or pain, foreign body sensation in the throat, fullness after meals, early satiety, abdominal pain, belching, anorexia, diarrhea, constipation, and unclean defecation. Many patients are accompanied by insomnia, anxiety, depression, headache, and other symptoms, and the course of the disease is often more than 6 months. The symptoms of the disease are complex, difficult to diagnose, easy to recur, and seriously endanger the physical and mental health and quality of life of patients. At present, clinical treatment mainly relies on gastrointestinal motility drugs, but long-term medication is prone to side effects and drug resistance, and many patients are difficult to achieve satisfactory results.

　　The biofeedback gastrointestinal motility instrument is developed based on the basic theory of 'gastrointestinal pacing', which is non-invasive, painless and has significant curative effect. It can not only accurately collect and analyze human gastrointestinal bioelectricity signals, objectively reflect patients' gastrointestinal peristalsis and gastrointestinal motility, provide reference for the treatment of various gastrointestinal diseases, but also effectively treat post meal discomfort syndrome, functional constipation, adverse reactions (anorexia, nausea, vomiting, constipation) caused by tumor radiotherapy and chemotherapy, and other diseases.

　　As an innovative product in the field of gastrointestinal disease diagnosis and treatment, the biofeedback gastrointestinal dynamic instrument has won more than ten national patents so far. Its appearance will help to further enrich medical service means and bring a new diagnosis and treatment experience to the majority of patients with gastrointestinal diseases.